×
About 190 results

ALLMedicine™ Adult Brain Tumor Center

Research & Reviews  66 results

Glioblastoma as a novel drug repositioning target: Updated state.
https://doi.org/10.2174/1871520623666230202163112
Anti-cancer Agents in Medicinal Chemistry; Hosseinalizadeh H, Ebrahimi A et. al.

Feb 4th, 2023 - Glioblastoma multiforme (GBM) is an aggressive form of adult brain tumor that can arise from a low-grade astrocytoma. In recent decades, several new conventional therapies have been developed that have significantly improved the prognosis of patie...

Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis
https://clinicaltrials.gov/ct2/show/NCT05413304

Feb 3rd, 2023 - Background Diffuse midline gliomas are the most aggressive brain tumors of childhood and young adults, with documented 2 year survival rates of <10%. These tumors are infiltrative midline high-grade gliomas. Treatment failure is due in part to the...

Association between preoperative platelet and 30-day postoperative mortality of adult p...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733164
BMC Neurology; Liu Y, Hu H et. al.

Dec 10th, 2022 - Evidence regarding the relationship between preoperative platelet and 30-day postoperative mortality of intracranial tumor patients undergoing craniotomy is still limited. Therefore, the present research was conducted to explore the link of the pl...

Assessment and prediction of glioblastoma therapy response: challenges and opportunities.
https://doi.org/10.1093/brain/awac450
Brain : a Journal of Neurology; Qi D, Li J et. al.

Nov 30th, 2022 - Glioblastoma is the most aggressive type of primary adult brain tumor. The median survival of patients with glioblastoma remains approximately 15 months, and the 5-year survival rate is less than 10%. Current treatment options are limited, and the...

TRAF4 Maintains Deubiquitination of Caveolin-1 to Drive Glioblastoma Stemness and Temoz...
https://doi.org/10.1158/0008-5472.CAN-21-3882
Cancer Research; Li Y, Wang T et. al.

Jul 28th, 2022 - Glioblastoma (GBM) is the most common type of primary adult brain tumor. Glioma stem cell (GSC) residence and temozolomide (TMZ) resistance in GBM both contribute to poor patient outcome. TRAF4 is a scaffold protein with E3 ubiquitin ligase activi...

see more →

Clinicaltrials.gov  5 results

Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral Microdialysis
https://clinicaltrials.gov/ct2/show/NCT05413304

Feb 3rd, 2023 - Background Diffuse midline gliomas are the most aggressive brain tumors of childhood and young adults, with documented 2 year survival rates of <10%. These tumors are infiltrative midline high-grade gliomas. Treatment failure is due in part to the...

Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor
https://clinicaltrials.gov/ct2/show/NCT01326104

Feb 7th, 2022 - Malignant brain tumors now represent the most frequent cause of cancer death in children. Despite aggressive and highly toxic multi-modality therapy including surgery, craniospinal radiation, and high-dose chemotherapy coupled with peripheral bloo...

A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma
https://clinicaltrials.gov/ct2/show/NCT02490930

Sep 13th, 2017 - Five evaluable patients with newly diagnosed high grade gliomas who will undergo standard concomitant radiation and temozolomide followed by adjuvant temozolomide will be accrued to this open-label, single arm, safety study. Oral fingolimod will b...

Adjunctive Donepezil Therapy and Genetic Risk Factors of Cognitive Dysfunction in Brain Tumor Survivors
https://clinicaltrials.gov/ct2/show/NCT00594633

Jan 14th, 2016 - A significant proportion of brain tumor patients treated with radiation or chemotherapy who are in disease remission experience cognitive sequelae from their treatment. Cognitive dysfunction can be of sufficient severity to interfere with their ab...

Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
https://clinicaltrials.gov/ct2/show/NCT01462695

Aug 27th, 2015 - PRIMARY OBJECTIVES: I. To estimate the objective response rate (partial response [PR] or complete response [CR] ≥ 8 weeks) to sunitinib in 2 strata (recurrent/progressive/refractory high-grade glioma vs ependymoma) of recurrent or progressive brai...

see more →

News  5 results

Enhancing Immune System May Boost Survival for Brain Cancer Patients
https://www.onclive.com/view/enhancing-immune-system-may-boost-survival-for-brain-cancer-patients

Oct 6th, 2021 - Jian Li Campian, MD, PhD Medical Oncologist Assistant Professor of Medicine Siteman Cancer Center Washington University School of Medicine St. Louis, MO The concept that the immune system plays a pivotal role in the prevention and co...

'Groundbreaking' Global Brain Cancer Trial Planned
https://www.onclive.com/view/groundbreaking-global-brain-cancer-trial-planned

Dec 20th, 2020 - Donald A. Berry, PhD An international coalition of experts is planning an innovative clinical trial aimed at speeding up the development of new treatments for patients with glioblastoma multiforme (GBM), putting into motion a biomarker-driven app...

Spinal Cord Ependymoma in the Prime of Life
https://www.onclive.com/view/spinal-cord-ependymoma-in-the-prime-of-life

Dec 5th, 2020 - Eric Kratky In January 2007, Erik Kratky was 21 and pursuing his undergraduate degree when he experienced bilateral leg weakness. Magnetic resonance imaging (MRI) revealed multiple spinal cord lesions in the T10 region and, after surgical resecti...

Alzheimer’s drug improves cognitive function after RT for brain tumors
https://www.mdedge.com/internalmedicine/article/98906/alzheimers-cognition/alzheimers-drug-improves-cognitive-function
Jennifer Kelly Shepphird

Apr 20th, 2015 - Adult brain tumor survivors taking donepezil, a drug approved for the treatment of Alzheimer’s disease, showed significant improvements in the cognitive functions of memory, motor speed, and dexterity, compared with those taking a placebo. However.

Gene and Pathway Alterations Identified in Both Glioblastoma Multiforme and Pancreatic Cancer
https://www.medscape.com/viewarticle/580110

Sep 5th, 2008 - September 5, 2008 — A trio of genomic studies published yesterday in Nature and Science point to specific genes and signaling pathways that characterize 2 human cancers. The results suggest a potential for targeted therapies in glioblastoma multif...

see more →